Any data displayed on the TriNetX Platform in aggregate form, or any patient level data provided in a data set generated by the TriNetX Platform, only contains de-identified data as per the de-identification standard defined in Section 164.514(a) of the HIPAA Privacy Rule. TriNetX is certified to the ISO 27001:2013 standard and maintains an Information Security Management System (ISMS) to ensure the protection of the healthcare data it has access to and to meet the requirements of the HIPAA Security Rule. The details of the IRB/oversight body that provided approval or exemption for the research described are given below: TriNetX is compliant with the Health Insurance Portability and Accountability Act (HIPAA), the US federal law which protects the privacy and security of healthcare data. The details of the IRB/oversight body that provided approval or exemption for the research described are given below: I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. TR002548-01), National Cancer Institute Case Comprehensive Cancer Center (CA221718, CA043703). AA029831), the Clinical and Translational Science Collaborative (CTSC) of Cleveland (grant no. AG057557, AG061388, AG062272, AG07664), National Institute on Alcohol Abuse and Alcoholism (grant no. ![]() We acknowledge support from the National Institute on Aging (grants nos. The authors have declared no competing interest. These data provide evidence that COVID-19 contributed to the 2022 surge of severe pediatric RSV cases. ![]() Among 228,940 children aged 0 –5 years, the risk for first-time medically attended RSV during 10/2022 –12/2022 was 6.40% for children with prior COVID-19 infection, higher than 4.30% for the matched children without COVID-19 (risk ratio or RR: 1.40, 95% CI: 1.27 –1.55) and among 99,105 children aged 0 –1 year, the overall risk was 7.90% for those with prior COVID-19 infection, higher than 5.64% for matched children without (RR: 1.40, 95% CI: 1.21 –1.62). The monthly incidence rate for first-time medically attended cases, most of which were severe RSV-associated diseases, reached a historical high rate of 2,182 cases per 1,0000,000 person-days in November 2022, corresponding to a related increase of 143% compared to expected peak rate (rate ratio: 2.43, 95% CI: 2.25 –2.63). Seasonal patterns of medically attended RSV infections were significantly disrupted during the COVID-19 pandemic. To assess whether COVID-19 contributed to this surge, we leveraged a real-time nation-wide US database of electronic health records (EHRs) using time series analysis from Januthrough January 31, 2023, and propensity-score matched cohort comparisons for children aged 0 –5 years with or without prior COVID-19 infection. ![]() Respiratory syncytial virus (RSV) infections and hospitalizations surged sharply in 2022 among young children.
0 Comments
Leave a Reply. |